PFKFB3 and pulmonary arterial hypertension: These findings suggest that PFKFB3 is a potential new therapeutic target for treating PAH; however, the detailed molecular mechanisms underlying PFKFB3 upregulation and glycolytic reprogramming in PAH remain to be elucidated.